Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARLENE C BULTEMEYER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1083828719
CMS profile
230389
Location
FORT WAYNE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$44,193.03

348 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 7 of 7; records 301–348 of 348 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARLENE C BULTEMEYER

NPI 1083828719 · CMS profile ID 230389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FORT WAYNE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 7 of 7; records 301–348 of 348 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083828719?year=2021&recipient=provider&page=7#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARLENE C BULTEMEYER, NPI 1083828719, CMS profile ID 230389. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 7; records 301–348 of 348 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083828719?year=2021&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARLENE C BULTEMEYER, NPI 1083828719, CMS profile ID 230389. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 7; records 301–348 of 348 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083828719?year=2021&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARLENE C BULTEMEYER, NPI 1083828719, CMS profile ID 230389, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 7; records 301–348 of 348 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1083828719?year=2021&recipient=provider&page=7#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

348 matching records · $44,193.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 348 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 301–348 of 348.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SK Life Science, Inc. $60.9203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826826791 CMS
AbbVie Inc. $2.2903/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185435 CMS
Mallinckrodt Hospital Products Inc. $19.7003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845348681 CMS
AbbVie Inc. $5.4603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185431 CMS
UCB, Inc. $73.0203/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807326779 CMS
AbbVie Inc. $5.8303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185423 CMS
AbbVie Inc. $1.1403/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185427 CMS
AbbVie Inc. $7.2003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185419 CMS
LivaNova USA, Inc. $4.7203/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844250899 CMS
LivaNova USA, Inc. $15.8003/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844250901 CMS
Biohaven Pharmaceuticals, Inc. $4.7903/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442663 CMS
AbbVie Inc. $4.8403/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185415 CMS
UCB, Inc. $13.1703/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807315343 CMS
UCB, Inc. $1.6903/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807315961 CMS
AbbVie Inc. $6.0803/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185411 CMS
Biohaven Pharmaceuticals, Inc. $124.9903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442659 CMS
ACADIA Pharmaceuticals Inc $9.1903/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837992125 CMS
ACADIA Pharmaceuticals Inc $2.2803/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837992129 CMS
Biohaven Pharmaceuticals, Inc. $5.0403/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442655 CMS
AbbVie Inc. $5.3602/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185407 CMS
Teva Pharmaceuticals USA, Inc. $1,000.0002/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839585293 CMS
AbbVie Inc. $10.5702/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185399 CMS
AbbVie Inc. $0.3302/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185403 CMS
AbbVie Inc. $11.7402/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185395 CMS
AbbVie Inc. $4.6202/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185387 CMS
AbbVie Inc. $5.2202/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185391 CMS
SK Life Science, Inc. $90.4802/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826826715 CMS
AbbVie Inc. $975.0002/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185383 CMS
UCB, Inc. $1.6002/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807304942 CMS
UCB, Inc. $7.6602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807304949 CMS
AbbVie Inc. $4.3302/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185379 CMS
Novartis Pharmaceuticals Corporation $11.3302/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812621721 CMS
AbbVie Inc. $13.2001/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185371 CMS
AbbVie Inc. $4.9901/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185375 CMS
SK Life Science, Inc. $2,175.0001/26/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826826831 CMS
Biohaven Pharmaceuticals, Inc. $4.4101/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442651 CMS
Biohaven Pharmaceuticals, Inc. $15.0001/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442643 CMS
Biohaven Pharmaceuticals, Inc. $2.4501/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442647 CMS
Biohaven Pharmaceuticals, Inc. $5.3901/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442639 CMS
Horizon Therapeutics plc $17.2401/15/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797086935 CMS
AbbVie Inc. $9.7401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185367 CMS
AbbVie Inc. $4.8701/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185363 CMS
Novartis Pharmaceuticals Corporation $14.4701/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812621719 CMS
Allergan, Inc. $750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792720807 CMS
Biohaven Pharmaceuticals, Inc. $5.4801/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852442635 CMS
LivaNova USA, Inc. $1,500.0001/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844250891 CMS
AbbVie Inc. $8.6501/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185355 CMS
AbbVie Inc. $12.6501/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794185359 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,781.69 235
PY2020 $23,635.15 113
PY2021 $44,193.03 348
PY2022 $48,005.26 391
PY2023 $51,118.26 258
PY2024 $55,741.95 84
PY2025 $40,368.76 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $51,758.59 62
PY2024 Principal investigator $41,575.10 50
PY2023 Principal investigator $19,180.80 14
PY2022 Principal investigator $9,000.00 1
PY2021 Principal investigator $11,353.14 11
PY2020 Principal investigator $86,936.40 3
PY2019 Principal investigator $28,632.68 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $848.90 12/23/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289802
Principal investigator 1 Ipsen Innovation $2,567.50 12/23/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289806
Principal investigator 1 Ipsen Innovation $848.90 12/23/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289808
Principal investigator 1 Ipsen Innovation $84.00 12/15/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289804
Principal investigator 1 Ipsen Innovation $90.00 12/11/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289478
Principal investigator 1 Ipsen Innovation $150.00 12/09/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289476
Principal investigator 1 Ipsen Innovation $848.90 11/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289790
Principal investigator 1 Ipsen Innovation $1,907.10 11/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289792
Principal investigator 1 Ipsen Innovation $848.90 11/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289794
Principal investigator 1 Ipsen Innovation $980.20 11/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289796
Principal investigator 1 Ipsen Innovation $2,033.20 11/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289800
Principal investigator 1 Ipsen Innovation $2,137.10 11/27/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289798
Principal investigator 1 UCB SA $27.89 11/25/2025 Non-covered Recipient Entity
MD FORT WAYNE NEUROLOGICAL CENTER - NEUROLOGY
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246659328
Principal investigator 1 Ipsen Innovation $1,708.20 10/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289788
Principal investigator 1 Ipsen Innovation $1,972.10 10/27/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289778
Principal investigator 1 Ipsen Innovation $84.50 10/27/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289782
Principal investigator 1 Ipsen Innovation $848.90 10/27/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289784
Principal investigator 1 Ipsen Innovation $84.50 10/27/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289786
Principal investigator 1 Ipsen Innovation $150.00 10/21/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289474
Principal investigator 1 Ipsen Innovation $1,708.20 10/16/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289780
Principal investigator 1 Ipsen Innovation $1,515.80 10/10/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289776
Principal investigator 1 Ipsen Innovation $180.00 09/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289470
Principal investigator 1 Ipsen Innovation $150.00 09/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289472
Principal investigator 1 Ipsen Innovation $84.50 08/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289770
Principal investigator 1 Ipsen Innovation $848.90 08/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289774
Principal investigator 1 Ipsen Innovation $75.00 08/13/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289772
Principal investigator 1 Ipsen Innovation $84.50 07/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289758
Principal investigator 1 Ipsen Innovation $420.00 07/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289760
Principal investigator 1 Ipsen Innovation $1,384.50 07/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289764
Principal investigator 1 Ipsen Innovation $84.50 07/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289768
Principal investigator 1 Ipsen Innovation $300.00 07/25/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289466
Principal investigator 1 Ipsen Innovation $300.00 07/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289464
Principal investigator 1 Ipsen Innovation $450.00 07/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289468
Principal investigator 1 Ipsen Innovation $500.00 07/04/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289762
Principal investigator 1 Ipsen Innovation $35.00 07/04/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289766
Principal investigator 1 Ipsen Innovation $1,972.10 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289736
Principal investigator 1 Ipsen Innovation $919.10 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289738
Principal investigator 1 Ipsen Innovation $2,445.30 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289740
Principal investigator 1 Ipsen Innovation $848.90 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289742
Principal investigator 1 Ipsen Innovation $848.90 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289744
Principal investigator 1 Ipsen Innovation $1,579.50 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289746
Principal investigator 1 Ipsen Innovation $1,511.90 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289748
Principal investigator 1 Ipsen Innovation $848.90 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289750
Principal investigator 1 Ipsen Innovation $848.90 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289752
Principal investigator 1 Ipsen Innovation $848.90 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289754
Principal investigator 1 Ipsen Innovation $1,579.50 06/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289756
Principal investigator 1 Ipsen Innovation $848.90 04/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289730
Principal investigator 1 Ipsen Innovation $848.90 04/30/2025 Covered Recipient Teaching Hospital
Indiana University Health
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289732
Principal investigator 1 Ipsen Innovation $848.90 04/28/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289446
Principal investigator 1 Ipsen Innovation $848.90 04/28/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289456
Principal investigator 1 Ipsen Innovation $84.50 04/28/2025 Covered Recipient Teaching Hospital
Indiana University Health
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289734
Principal investigator 1 Ipsen Innovation $270.00 04/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289448
Principal investigator 1 Ipsen Innovation $150.00 04/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289450
Principal investigator 1 Ipsen Innovation $150.00 04/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289452
Principal investigator 1 Ipsen Innovation $90.00 04/16/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289454
Principal investigator 1 Ipsen Innovation $300.00 04/09/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289458
Principal investigator 1 Ipsen Innovation $180.00 04/09/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289460
Principal investigator 1 Ipsen Innovation $150.00 04/09/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184289462
Principal investigator 1 Ipsen Innovation $1,846.00 01/31/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289444
Principal investigator 1 Ipsen Innovation $848.90 01/27/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184289442
Principal investigator 1 UCB SA $1,850.00 01/17/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS, INC
An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures No dispute reported 06/30/2026 1246656966
Principal investigator 1 UCB SA $1,850.00 01/17/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS, INC
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246657366